Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;10(10):1129-1166.
doi: 10.1002/ueg2.12305. Epub 2022 Sep 16.

Landscape of new drugs and targets in inflammatory bowel disease

Sophie Vieujean  1 , Ferdinando D'Amico  2   3 , Patrick Netter  4 , Silvio Danese  2 , Laurent Peyrin-Biroulet  5   6
Affiliations
Review

Landscape of new drugs and targets in inflammatory bowel disease

Sophie Vieujean et al. United European Gastroenterol J. 2022 Dec.

Abstract

Although the therapeutic armamentarium of Inflammatory bowel diseases (IBD) physicians has expanded rapidly in recent years, a proportion of patients remain with a suboptimal response to medical treatment due to primary no response, loss of response or intolerance to currently available drugs. Our growing knowledges of IBD pathophysiology has led to the development of a multitude of new therapies over time, which may, 1 day, be able to address this unmet medical need. This review aims to provide physicians an update of emerging therapies in IBD by focusing on drugs currently in phase 3 clinical trials. Among the most promising molecules are anti-IL-23, JAK-inhibitors, anti-integrins and S1P modulators. While the results in terms of efficacy and safety are fairly clear for some classes, the question of safety remains more uncertain for other classes. Molecules at a more preliminary stage of development (phase 1 and 2), one of which may 1 day offer an optimal benefit-risk ratio, will also be presented as well as their respective mechanisms of action.

Keywords: clinical trials; inflammatory bowel disease; new drugs; phase 1; phase 2; phase 3.

PubMed Disclaimer

Conflict of interest statement

Sophie Vieujean declares no conflict of interest.

Ferdinando D’Amico declares no conflict of interest.

Silvio Danese has served as a speaker, consultant, and advisory board member for Schering‐Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor.

Laurent Peyrin‐Biroulet: personal fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Inotrem, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine; Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, Theravance; Pandion Therapeutics, grants from Abbvie, MSD, Takeda, Fresenius Kabi, stock options: CTMA.

Figures

FIGURE 1
FIGURE 1
UC (a) and Crohn's disease (CD) (b) drugs pipeline. Outer ring: Phase 1, Middle ring: Phase 2, Inner circle: Phase 3. 5‐ASA, 5‐aminosalicylic acid; CSF‐1R, Colony Stimulating Factor‐1 Receptor; DNA, deoxyribonucleic acid; FKN, fractalkine; HDAC, Histone deacetylase inhibitor; IFX, infliximab; IL, interleukin; Inhib., inhibitor; LANCL2, Lanthionine synthetase C‐like 2; MAP, mycobacterium avium subspecies paratuberculosis; NLRX1, nucleotide‐binding oligomerization domain, leucine rich repeat containing X1; R, receptor; SGLT2, sodium/glucose cotransporter 2; S1P, sphingosine‐1‐phosphate; SGLT2, sodium/glucose cotransporter 2; SIK, salt‐inducible kinase; TLR, toll like receptor; UST, ustekinumab
See this image and copyright information in PMC

References

    1. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9. 10.1016/S0140-6736(02)08512-4 - DOI - PubMed
    1. Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, et al. Long‐term infliximab maintenance therapy for ulcerative colitis: the ACT‐1 and ‐2 extension studies. Inflamm Bowel Dis. 2012;18(2):201–11. 10.1002/ibd.21697 - DOI - PubMed
    1. Karmiris K, Paintaud G, Noman M, Magdelaine‐Beuzelin C, Ferrante M, Degenne D, et al. Influence of trough serum levels and immunogenicity on long‐term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137(5):1628–40. 10.1053/J.GASTRO.2009.07.062 - DOI - PubMed
    1. Lichtenstein GR, Thomsen O, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn’s disease for up to 18 months. Clin Gastroenterol Hepatol. 2010;8(7):600–9. 10.1016/J.CGH.2010.01.014 - DOI - PubMed
    1. Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, et al. Long‐term benefit of golimumab for patients with moderately to severely active ulcerative colitis: results from the PURSUIT‐maintenance extension. J Crohns Colitis. 2018;12(9):1053–66. 10.1093/ECCO-JCC/JJY079 - DOI - PubMed

Publication types

MeSH terms

Substances